Reply to ‘Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials’

We read with interest the recent article by Rungapiromnan et al. that utilized a meta-analysis to compile data from 38 randomized controlled trials (RCTs) to determine if there is an association between biologic therapies and major adverse cardiovascular events (MACEs) in patients with plaque psoriasis. In the current study, only 10 MACEs were reported over nine of the RCTs examined. The reported absolute values of the Peto odds ratios are worthy of attention.

This article is protected by copyright. All rights reserved.

http://ift.tt/2oSbNAQ